www.neurologylive.com
THC/CBD Combination Cuts Agitation in Hospice-Eligible Dementia: LiBBY Trial | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting its ...